Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on July 8, 2005
Japanese Journal of Clinical Oncology 2005 35(8):433-438; doi:10.1093/jjco/hyi127
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
35/8/433    most recent
hyi127v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Maruyama, R.
Right arrow Articles by Ichinose, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maruyama, R.
Right arrow Articles by Ichinose, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2005 Foundation for Promotion of Cancer Research

Triplet Chemotherapy with Cisplatin, Gemcitabine and Vinorelbine for Malignant Pleural Mesothelioma

Riichiroh Maruyama, Fumihiro Shoji, Tatsuro Okamoto, Tetsuya Miyamoto, Tetsuro Miyake, Tomomi Nakamura, Jiro Ikeda, Yoshiro Aoki, Hiroshi Wataya, Hiroshi Asoh and Yukito Ichinose

Department of Thoracic Oncology, Kyushu Cancer Center, Fukuoka, Japan

For reprints and all correspondence: Dr Riichiroh Maruyama, Department of Thoracic Oncology, Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka 811-1395, Japan. E-mail: rmaruyama{at}nk-cc.go.jp

Received February 22, 2005; accepted June 1, 2005

Background: The incidence of malignant pleural mesothelioma (MPM) is expected to increase due to delayed control of occupational exposure to asbestos in Japan. We investigated the use of triplet combination chemotherapy with cisplatin (CDDP), gemcitabine (GEM) and vinorelbine (VNR) for the treatment of Japanese patients with MPM.

Methods: From December 2000 to August 2003, 12 patients received the following regimen: CDDP 40 mg/m2, GEM 800 mg/m2 and VNR 20 mg/m2 on days 1 and 8 every 4 weeks. Among the 12 patients, six selected patients underwent an extrapleural pneumonectomy (EP) after a median of three cycles of triplet chemotherapy.

Results: The overall response rate for all patients and the response rate for chemotherapy-naive cases were 58 and 67%, respectively. The median survival time and survival rate at 2 years for all patients were 11 months and 50%, respectively. The 2-year survival rates for the patients with and without EP were 83.3 and 16.7%, respectively.

Conclusions: Triplet chemotherapy with CDDP, GEM and VNR was thus found to be highly effective for patients with MPM and its toxicity was manageable. A multi-institutional phase II trial is now being planned to establish the effectiveness of this new regimen in chemotherapy-naive patients with MPM.

Key Words: malignant pleural mesothelioma • triplet chemotherapy • extrapleural pneumonectomy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
R. Maruyama, M. Sakai, T. Nakamura, R. Suemitsu, T. Okamoto, H. Wataya, K. Nishiyama, T. Kamei, and Y. Ichinose
Triplet Chemotherapy for Malignant Pericardial Mesothelioma: A Case Report
Jpn. J. Clin. Oncol., April 1, 2006; 36(4): 245 - 248.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.